AB Science Records Fourth Efficacy Signal with AB8939 in AML
The French biopharmaceutical group AB Science announced on the evening of January 7 a fourth consecutive clinical response observed with the combination of AB8939 and venetoclax in a patient with refractory or relapsed acute myeloid leukemia (AML) in its phase 1 study.
Patient Profile and Treatment
The patient in question exhibited a particularly unfavorable genetic profile and was treated with AB8939 at a dose of 21.3 mg/m² combined with venetoclax for 14 days. Under this combination, a partial response was observed, a result deemed consistent with the data already communicated for the first three treated patients.
Preliminary Data Insights
According to the investigators, these preliminary data suggest a reproducible clinical activity and a tolerance compatible with the continuation of development, especially in high-risk patients likely to resist standard venetoclax-based treatments.
Future Development Plans
AB Science now plans to finalize phase 1 of the AB8939 + venetoclax combination, before launching an extension study on about 15 patients, aimed at consolidating efficacy evidence and supporting the next steps of clinical and regulatory development.
